Hypoxia-inducible factor inhibitors: a survey of recent patented compounds (2004 – 2010)

Bibliography

• Semenza GL, Wang GL. A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. Mol Cell Biol 1992;12:5447-54
   PubMed Web of Science ®Google Scholar
• Shweiki D, Itin A, Soffer D, Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992;359:843-5
   PubMed Web of Science ®Google Scholar
• Wang GL, Jiang BH, Rue EA, Hypoxia-inducible factor-1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci USA 1995;92:5510-14
   PubMed Web of Science ®Google Scholar
• Iwai K, Yamanaka K, Kamura T, Identification of the von Hippel-lindau tumor-suppressor protein as part of an active E3 ubiquitin ligase complex. Proc Natl Acad Sci USA 1999;96:12436-41
   PubMed Web of Science ®Google Scholar
• Maxwell PH, Wiesener MS, Chang GW, The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 1999;399:271-5
   PubMed Web of Science ®Google Scholar
• Ohh M, Park CW, Ivan M, Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein. Nat Cell Biol 2000;2:423-7
   PubMed Web of Science ®Google Scholar
• Yu F, White SB, Zhao Q, HIF-1alpha binding to VHL is regulated by stimulus-sensitive proline hydroxylation. Proc Natl Acad Sci USA 2001;98:9630-5
   PubMed Web of Science ®Google Scholar
• Cockman ME, Masson N, Mole DR, Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein. J Biol Chem 2000;275:25733-41
   PubMed Web of Science ®Google Scholar
• Kallio PJ, Wilson WJ, O'Brien S, Regulation of the hypoxia-inducible transcription factor 1alpha by the ubiquitin-proteasome pathway. J Biol Chem 1999;274:6519-25
   PubMed Web of Science ®Google Scholar
• Berra E, Richard DE, Gothie E, HIF-1-dependent transcriptional activity is required for oxygen-mediated HIF-1alpha degradation. FEBS Lett 2001;491:85-90
   PubMed Web of Science ®Google Scholar
• Hewitson KS, McNeill LA, Riordan MV, Hypoxia-inducible factor (HIF) asparagine hydroxylase is identical to factor inhibiting HIF (FIH) and is related to the cupin structural family. J Biol Chem 2002;16:1466-71
   Google Scholar
• Jaakkola P, Mole DR, Tian YM, Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 2001;292:468-72
   PubMed Web of Science ®Google Scholar
• Ivan M, Kondo K, Yang H, HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science 2001;292:464-8
   PubMed Web of Science ®Google Scholar
• Wenger RH. Cellular adaptation to hypoxia: O2-sensing protein hydroxylases, hypoxia-inducible transcription factors, and O2-regulated gene expression. FASEB J 2002;16:1151-62
   PubMed Web of Science ®Google Scholar
• Zhong H, De Marzo AM, Laughner E, Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res 1999;59:5830-5
   PubMed Web of Science ®Google Scholar
• Folkman J. Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov 2007;6:273-86
   PubMed Web of Science ®Google Scholar
• Pouyssegur J, Dayan F, Mazure NM. Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature 2006;441:437-43
   PubMed Web of Science ®Google Scholar
• Bertout JA, Patel SA, Simon MC. The impact of O2 availability on human cancer. Nat Rev Cancer 2008;8:967-75
   PubMed Web of Science ®Google Scholar
• Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003;3:721-32
   PubMed Web of Science ®Google Scholar
• Kirkpatrick DL, Kuperus M, Dowdeswell M, Mechanisms of inhibition of the thioredoxin growth factor system by antitumor 2-imidazolyl disulfides. Biochem Pharmacol 1998;55:987-94
   PubMed Web of Science ®Google Scholar
• Welsh SJ, Williams RR, Birmingham A, The thioredoxin redox inhibitors1-methylpropyl 2-imidazolyl disulfide and pleurotin inhibit hypoxia-induced factor 1a and vascular endothelial growth factor formation. Mol Cancer Ther 2003;2:235-43
   PubMed Web of Science ®Google Scholar
• Ramanathan RK, Kirkpatrick DL, Belani CP, A phase 1 pharmacokinetic and pharmacodynamic study of PX-12, a novel inhibitor of thioredoxin-1, in patients with advanced solid tumors. Clin Cancer Res 2007;13:2109-14
   PubMed Web of Science ®Google Scholar
• ProlX Pharmaceuticals. Compositions and methods for using asymmetric disulfides. WO082686; 2009
   Google Scholar
• Ramanathan RK, Abbruzzese J, Dragovich T, A randomized phase II study of PX-12, an inhibitor of thioredoxin in patients with advanced cancer of the pancreas following progression after a gemcitabine-containing combination. Cancer Chemother Pharmacol 12 May 2010. [Epub ahead of print] DOI: 10.1007/s00280-010-1343-8
   Google Scholar
• Welsh S, Williams R, Kirkpatrick L, Antitumor activity and pharmacodynamic properties of PX-478, an inhibitor of hypoxia-inducible factor-1alpha. Mol Cancer Ther 2004;3:233-44
   PubMed Web of Science ®Google Scholar
• ProlX Pharmaceuticals. N-Oxides and derivatives of melphalan for treating diseased states associated with hypoxia inducible factor. WO043359; 2004
   Google Scholar
• ProlX Pharmaceuticals. Regulation of HIF protein levels via deubiquitinatio pathways. WO007828; 2005
   Google Scholar
• Ravi R, Mookerjee B, Bhujwalla ZM, Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha. Genes Dev 2000;14:34-44
   PubMed Web of Science ®Google Scholar
• ProlX Pharmaceuticals. Method of pre-selecting patients for anti-VEGF, anti-HIF-1 or anti-thioredoxin therapy. WO023658; 2006
   Google Scholar
• Board of regents of the University of Texas System. Compositions and methods for treating lung cancer. WO102960; 2009
   Google Scholar
• Tibes R, Falchook GS, Von Hoff DD, Results from a phase I, dose-escalation study of PX-478, an orally available inhibitor of HIF-1alpha. J Clin Oncol 2010;28(Suppl):3076
   PubMedGoogle Scholar
• Teng CM, Wu CC, Ko FN, YC-1, a nitric oxide-independent activator of soluble guanylate cyclase, inhibits platelet-rich thrombosis in mice. Eur J Pharmacol 1997;320:161-6
   PubMed Web of Science ®Google Scholar
• Galle J, Zabel U, Hubner U, Effects of the soluble guanylyl cyclase activator, YC-1, on vascular tone, cyclic GMP levels and phosphodiesterase activity. Br J Pharmacol 1999;127:195-203
   PubMed Web of Science ®Google Scholar
• Chun YS, Yeo EJ, Choi E, Inhibitory effect of YC-1 on the hypoxic induction of erythropoietin and vascular endothelial growth factor in Hep3B cells. Biochem Pharmacol 2001;61:947-54
   PubMed Web of Science ®Google Scholar
• Hif Bio, Inc. Method for inhibiting tumor angiogenesis and tumor growth. WO091648; 2004
   Google Scholar
• Hif Bio, Inc. Compounds, compositions and methods. WO030121; 2005
   Google Scholar
• Hif Bio, Inc. Anti-angiogenesis compounds. WO065010; 2007
   Google Scholar
• Emory University and Scripps Research Institute. HIF-1 inhibitors. WO087066; 2004
   Google Scholar
• Emory University and Scripps Research Institute. HIF inhibitors. WO025169; 2007
   Google Scholar
• Nicolaou KC, Pfefferkorn JA, Roecker, AJ, Natural product-like combinatorial libraries based on privileged structures. 1. General principles and solid-phase synthesis of benzopyrans. J Am Chem Soc 2000;122:9939-53
   Web of Science ®Google Scholar
• Nicolaou KC, Pfefferkorn JA, Mitchell HJ, Natural product-like combinatorial libraries based on privileged structures. 2. Construction of a 10000-membered benzopyran library by directed split-and-pool chemistry using NanoKans and optical encoding. J Am Chem Soc 2000;122:9954-67
   Web of Science ®Google Scholar
• Nicolaou KC, Pfefferkorn JA, Barluenga S, Natural Product-like Combinatorial Libraries based on privileged structures. 3. The ‘Libraries from Libraries’ Principle for diversity enhancement of benzopyran libraries. J Am Chem Soc 2000;122:9968-76
   Web of Science ®Google Scholar
• Emory University. Small molecule inhibitors of HIF and angiogenesis. WO006184; 2010
   Google Scholar
• Emory University and Scripps Research Institute. Small molecule inhibitors of HIF and angiogenesis. WO006189; 2010
   Google Scholar
• National Cancer Institute. Trcyclic compounds as inhibitors of the hypoxic signal pathway. WO118580; 2005
   Google Scholar
• Lee HH, Palmer BD, Boyd M, Potential antitumor agents. 64. Synthesis and antitumor evaluation of dibenzo1,4]dioxin-1-carboxamides: a new class of weakly binding DNA-intercalating agents. J Med Chem 1992;35:258-66
   PubMedGoogle Scholar
• Creighton-Gutteridge M, Cardellina JH II, Stephen AG, Cell type-specific, topoisomerase II-dependent inhibition of hypoxia-inducible factor-1alpha protein accumulation by NSC 644221. Clin Cancer Res 2007;13:1010-18
   PubMedGoogle Scholar
• Cell TherapeuticsEuro S.R.L. Use of thiazolidinone derivatives as antiangiogenic agents. WO066846; 2006
   Google Scholar
• University of Texas. Compositions and methods for inhibition of tyrosine kinases. WO030795; 2008
   Google Scholar
• Piramal Life Sciences Ltd. Pyridyl derivatives, their preparation and use. WO019656; 2009
   Google Scholar
• Yewalkar N, Deore V, Padgaonkar A, Development of novel inhibitors targeting HIF-1alpha towards anticancer drug discovery. Bioorg Med Chem Lett 2010;20:6426-9
   PubMedGoogle Scholar
• Noguchi T, Fujimoto H, Sano H, Angiogenesis inhibitors derived from thalidomide. Bioorg Med Chem Lett 2005;15:5509-13
   PubMed Web of Science ®Google Scholar
• Charlesson LLC. Thalidomide analogs for treating vascular abnormalities. WO154353; 2008
   Google Scholar
• Charlesson LLC homepage. Available from: http://www.charlessonllc.com/index.html
   Google Scholar
• Bayer Schering Pharma AG. Heteroaryl substituted pyrazole derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis. WO141731; 2008
   Google Scholar
• Bayer Schering Pharma AG. Aminoalkyl-substituted compounds as HIF inhibitors. WO054762; 2010
   Google Scholar
• Bayer Schering Pharma AG. Heterocyclically substituted aryl compounds as HIF inhibitors. WO054763; 2010
   Google Scholar
• Bayer Schering Pharma AG. Heteroaromatic compounds for use as HIF inhibitors. WO054764; 2010
   Google Scholar
• Korea Research Institute of Bioscience and Biotechnology. Compounds that inhibit HIF-1 activity, the method for preparation thereof and the pharmaceutical composition containing them as an effective component. WO004798; 2008
   Google Scholar
• Lee K, Kang JE, Park SK, LW6, a novel HIF-1 inhibitor, promotes proteasomal degradation of HIF-1alpha via upregulation of VHL in a colon cancer cell line. Biochem Pharmacol 2010;80:982-9
   PubMed Web of Science ®Google Scholar
• Lee K, Lee JH, Boovanahalli SK, (Aryloxyacetylamino)benzoic acid analogues: A new class of hypoxia-inducible factor-1 inhibitors. J Med Chem 2007;50:1675-84
   PubMed Web of Science ®Google Scholar
• Won MS, Im N, Park S, A novel benzimidazole analogue inhibits the hypoxia-inducible factor (HIF)-1 pathway. Biochem Biophys Res Commun 2009;385:16-21
   PubMed Web of Science ®Google Scholar
• Shimizu K, Maruyama M, Yasui Y, Boron-containing phenoxyacetanilide derivatives as hypoxia-inducible factor (HIF)-1alpha inhibitors. Bioorg Med Chem Lett 2010;20:1453-6
   PubMed Web of Science ®Google Scholar
• Ban HS, Shimizu K, Minegishi H, Identification of HSP60 as a primary target of o-carboranylphenoxyacetanilide, an HIF-1alpha inhibitor. J Am Chem Soc 2010;132:11870-1
   PubMed Web of Science ®Google Scholar
• Centro de Investigacion Principe Felipe. Pharmaceutical composition for inhibiting the transcription factor inducible by hypoxia, modulators of pathological processes of angiogenesis, oncogenesis, inflammation, apoptosis, and cellular therapy. WO112615; 2009
   Google Scholar
• Moreno-Manzano V, Rodríguez-Jimenez FJ, Acena-Bonilla JL, FM19G11, a new hypoxia-inducible factor (HIF) modulator, affects stem cell differentiation status. J Biol Chem 2010;285:1333-42
   PubMed Web of Science ®Google Scholar
• Rodriguez-Jimenez FJ, Moreno-Manzano V, Mateos-Gregorio P, FM19G11: a new modulator of HIF that links mTOR activation with the DNA damage checkpoint pathways. Cell Cycle 2010;9:2803-13
   Google Scholar
• Threshold Pharmaceuticals. Combination therapies for the treatment of cancer. WO064734; 2004
   Google Scholar
• Cell Therapeutics Europe S.R.L. Indole derivatives with antitumor activity. WO066923; 2006
   Google Scholar
• Bionaut Pharmaceuticals. Anti-neoplastic agents, combination therapies and related methods. WO060951; 2005
   Google Scholar
• Bionaut Pharmaceuticals. Pancreatic cancer treatment using Na+/K+ ATPase inhibitors. WO028969; 2006
   Google Scholar
• Bionaut Pharmaceuticals. Treatments of refractory cancers using Na+/K+ ATPase inhibitors. WO029020; 2006
   Google Scholar
• Bionaut Pharmaceuticals. Combinatorial chemotherapy treatment using Na+/K+ ATPase inhibitors. WO029018; 2006
   Google Scholar
• Bionaut Pharmaceuticals. Use of Na+/K+ ATPase inhibitors and antagonists thereof. WO044916; 2006
   Google Scholar
• Bionaut Pharmaceuticals. Modulators of hypoxia inducible factor-1 and related uses for the treatment of ocular disorders. WO016656; 2007
   Google Scholar
• Btg International. Modulators of hypoxia inducible factor-1 and related uses. WO081835; 2007
   Google Scholar
• Btg International. Modulators of hypoxia inducible factor-1 and related uses. WO093086; 2008
   Google Scholar
• Sri International. Method and composition for inhibiting cell proliferation and angiogenesis. WO113842; 2006
   Google Scholar
• Duellman SJ, Calaoagan JM, Sato BG, A novel steroidal inhibitor of estrogen-related receptor alpha (ERRalpha). Biochem Pharmacol 2010;80:819-26
   PubMed Web of Science ®Google Scholar
• California Institute of Technology. Compositions and methods for inhibiting expression of hypoxia-inducible genes. WO120582; 2005
   Google Scholar
• Aileron Therapeutics. Peptidomimetic macrocycles. WO034028; 2010
   Google Scholar
• Whitesell L, Mimnaugh EG, De Costa B, Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation. Proc Natl Acad Sci USA 1994;91:8324-8
   PubMed Web of Science ®Google Scholar
• Kaur G, Belotti D, Burger AM, Antiangiogenic properties of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin: an orally bioavailable heat shock protein 90 modulator. Clin Cancer Res 2004;10:4813-21
   PubMed Web of Science ®Google Scholar
• Mabjeesh NJ, Post DE, Willard MT, Geldanamycin induces degradation of hypoxia-inducible factor 1alpha protein via the proteosome pathway in prostate cancer cells. Cancer Res 2002;62:2478-82
   PubMed Web of Science ®Google Scholar
• Isaacs JS, Jung YJ, Mimnaugh EG, Hsp90 regulates a von Hippel Lindau-independent hypoxia-inducible factor-1alpha-degradative pathway. J Biol Chem 2002;277:29936-44
   PubMed Web of Science ®Google Scholar
• Liu YV, Baek JH, Zhang H, RACK1 competes with HSP90 for binding to HIF-1alpha and is required for O2-independent and HSP90 inhibitor-induced degradation of HIF-1alpha. Mol Cell 2007;25:207-17
   PubMed Web of Science ®Google Scholar
• Massachusetts Eye & Ear Infirmary. Inflammatory eye disease. WO105077; 2005
   Google Scholar
• Kamal A, Thao L, Sensintaffar J, A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature 2003;425:407-10
   PubMed Web of Science ®Google Scholar
• Ronnen EA, Kondagunta GV, Ishill N, A phase II trial of 17-(Allylamino)-17-demethoxygeldanamycin in patients with papillary and clear cell renal cell carcinoma. Invest New Drugs 2006;24:543-6
   PubMed Web of Science ®Google Scholar
• Pacey S, Gore M, Chao D, A Phase II trial of 17-allylamino, 17-demethoxygeldanamycin (17-AAG, tanespimycin) in patients with metastatic melanoma. Invest New Drugs 5 Aug 2010. [Epub ahead of print] DOI: 10.1007/s10637-010-9493-4
   Google Scholar
• Richardson PG, Chanan-Khan AA, Alsina M, Tanespimycin monotherapy in relapsed multiple myeloma: results of a phase 1 dose-escalation study. Br J Haematology 2010;150:438-45
   PubMed Web of Science ®Google Scholar
• Vaishampayan UN, Burger AM, Sausville EA, Safery, efficacy, pharmacokinetics, and pharmacodynamics of the combination of sorafenib and tanespimycin. Clin Cancer Res 2010;16:3795-804
   PubMed Web of Science ®Google Scholar
• Isham CR, Tibodeau JD, Jin W, Chaetocin: a promising new antimyeloma agent with in vitro and in vivo activity mediated via imposition of oxidative stress. Blood 2007;109:2579-88
   Google Scholar
• Cell Therapeutics Europe S.R.L. Use of diketodithiopiperazine antibiotics for the preparation of antiangiogenic pharmaceutical compositions. WO066775; 2006
   Google Scholar
• Rao KV, Puri VN, Diwan PK, Preliminary evaluation of manassantin A, a potential neuroleptic agent from Saururus cernuus. Pharmacol Res Commun 1987;19:629-38
   PubMedGoogle Scholar
• Hwang BY, Lee J-H, Nam JB, Lignans from Saururus chinensis inhibiting the transcription factor NF-kappaB. Phytochemistry 2003;64:765-71
   PubMed Web of Science ®Google Scholar
• Lee WS, Lee D-W, Baek Y-I, Human ACAT-1 and -2 inhibitory activities of saucerneol B, manassantin A and B isolated from Saururus chinensis. Bioorg Med Chem Lett 2004;14:3109-12
   PubMed Web of Science ®Google Scholar
• Lee JH, Hwang BY, Kim KS, Suppression of RelA/p65 transactivation activity by a lignoid manassantin isolated from Saururus chinensis. Biochem Pharmacol 2003;66:1925-33
   PubMedGoogle Scholar
• The University of Mississippi. Saururus cernuus compounds that inhibit cellular responses to hypoxia. WO110348; 2004
   Google Scholar
• Duke University. Manassantin compounds and methods of making and using same. WO059858; 2010
   Google Scholar
• University of Arizona. Wortmannin analogs and methods using same. WO024183; 2003
   Google Scholar
• Le Cras TD, Korfhagen TR, Davidson C, Inhibition of PI3K by PX-866 prevents transforming growth factor-alpha-induced pulmonary fibrosis. Am J Pathology 2010;176:679-86
   PubMedGoogle Scholar
• Enzon Pharmaceuticals, Inc. Potent LNA oligonucleotides for the inhibition of HIF-1a expression. WO0286859; 2009
   Google Scholar
• Enzon Pharmaceuticals, Inc. Oligomeric compounds for the modulation of HIF-1alpha expression. WO0093839; 2010
   Google Scholar
• Greenberger LM, Horak ID, Filpula D, A RNA antagonist of hypoxia-inducible factor-1alpha. EZN-2968, inhibits tumor cell growth. Mol Cancer Thr 2008;7:3598-608
   PubMed Web of Science ®Google Scholar
• Patnaik A, Chiorean EG, Tolcher A, EZN-2968, anovel hypoxia-inducible factor-1alpha (HIF-1alpha) messanger ribonucleic acid (mRNA) antagonist: results of a phase I, pharmacokinetics (PK), dose-escalation study of daily administration in patients (pts) with advanced malignancies. J Clin Oncol 2009;27: abstract 2564
   PubMedGoogle Scholar
• Wang GL, Semenza GL. Purification and characterization of hypoxia-inducible factor 1. J Biol Chem 1995;270:1230-7
   PubMed Web of Science ®Google Scholar
• Yan L, Colandrea VJ, Hale JJ, Prolyl hydroxylase domain-containing protein inhibitors as stabilizers of hypoxia-inducible factor: small molecule-based therapeutics for anemia. Expert Opin Ther Patients 2010;20;1219-45
   PubMed Web of Science ®Google Scholar
• Diaz-Gonzalez JA, Russell J, Rouzaut A, Targeting hypoxia and angiogenesis through HIF-1alpha inhibition. Cancer Biol Ther 2005;4:1055-62
   PubMed Web of Science ®Google Scholar
• Liu P, Cheng H, Roberts, TM, Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov 2009;8:627-44
   PubMed Web of Science ®Google Scholar
• Aebersold DM, Burri P, Beer KT, Expression of hypoxia-inducible factor-1alpha: a novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer. Cancer Res 2001;61:2911-16
   PubMed Web of Science ®Google Scholar
• Schwartz DL, Powis G, Thitai-Kumar A, The selective hypoxia inducible factor-1 inhibitor PX-478 provides in vivo radiosensitization through tumor stromal effects. Mol Cancer Ther 2009;8:947-58
   PubMed Web of Science ®Google Scholar